Literature DB >> 34304580

Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.

RuiJun Chen1,2, Marc A Suchard3,4, Harlan M Krumholz5,6, Martijn J Schuemie3,7, Steven Shea8, Jon Duke9, Nicole Pratt10, Christian G Reich11, David Madigan12, Seng Chan You13, Patrick B Ryan1, George Hripcsak1,14.   

Abstract

[Figure: see text].

Entities:  

Keywords:  angiotensin receptor; angiotensin receptor blocker; cardiovascular outcomes; hypertension; safety

Mesh：

Substances：

Year:  2021        PMID： 34304580      PMCID： PMC8363588          DOI： 10.1161/HYPERTENSIONAHA.120.16667

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   9.897


  43 in total

1.  CORD: COmparison of Recommended Doses of ace inhibitors and angiotensin II receptor blockers.

Authors:  J Spinar; J Vítovec; M Souček; L Dušek; T Pavlík
Journal:  Int J Cardiol       Date:  2009-03-17       Impact factor: 4.164

2.  Accuracy of an automated knowledge base for identifying drug adverse reactions.

Authors:  E A Voss; R D Boyce; P B Ryan; J van der Lei; P R Rijnbeek; M J Schuemie
Journal:  J Biomed Inform       Date:  2016-12-16       Impact factor: 6.317

Review 3.  Drug-induced acute pancreatitis: a review.

Authors:  Mark R Jones; Oliver Morgan Hall; Adam M Kaye; Alan David Kaye
Journal:  Ochsner J       Date:  2015

Review 4.  Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.

Authors:  Edmond C K Li; Balraj S Heran; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2014-08-22

Review 5.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  J Am Coll Cardiol       Date:  2017-11-13       Impact factor: 24.094

Review 6.  Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?

Authors:  Franz H Messerli; Sripal Bangalore; Chirag Bavishi; Stefano F Rimoldi
Journal:  J Am Coll Cardiol       Date:  2018-04-03       Impact factor: 24.094

7.  Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP).

Authors:  Ingo A Eland; Anders Sundström; Giancarlo P Velo; Morten Andersen; Miriam C J M Sturkenboom; Michael J S Langman; Bruno H Ch Stricker; Beje Wiholm
Journal:  Scand J Gastroenterol       Date:  2006-12       Impact factor: 2.423

Review 8.  Kallikrein-kinin system in acute pancreatitis: potential of B(2)-bradykinin antagonists and kallikrein inhibitors.

Authors:  T Griesbacher
Journal:  Pharmacology       Date:  2000-04       Impact factor: 2.547

9.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

10.  Antihypertensive drugs and the risk of gastrointestinal bleeding.

Authors:  S Suissa; C Bourgault; A Barkun; O Sheehy; P Ernst
Journal:  Am J Med       Date:  1998-09       Impact factor: 4.965
View more
  9 in total

Review 1.  Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity?

Authors:  Zachary A Marcum; Jordana B Cohen; Eric B Larson; Jeff Williamson; Adam P Bress
Journal:  NAM Perspect       Date:  2022-05-09

Review 2.  Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations.

Authors:  Giovanna Gallo; Massimo Volpe; Speranza Rubattu
Journal:  Vasc Health Risk Manag       Date:  2022-07-11

3.  Impact of Antihypertensive Drug Class on Outcomes in SPRINT.

Authors:  Douglas D DeCarolis; Amy Gravely; Christine M Olney; Areef Ishani
Journal:  Hypertension       Date:  2022-03-09       Impact factor: 9.897

Review 4.  New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy.

Authors:  Aikaterini Damianaki; Erietta Polychronopoulou; Gregoire Wuerzner; Michel Burnier
Journal:  High Blood Press Cardiovasc Prev       Date:  2021-12-15

5.  Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias.

Authors:  Tobias Schupp; Michael Behnes; Mohammad Abumayyaleh; Kathrin Weidner; Kambis Mashayekhi; Thomas Bertsch; Ibrahim Akin
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

6.  Comparative efficacy and safety of fimasartan in patients with hypertension: A network meta-analysis of randomized controlled trials.

Authors:  Suk Min Seo; Sang Hyun Ihm; Jeong-Eun Yi; Seung Hee Jeong; Bong-Seog Kim
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-07-12       Impact factor: 2.885

7.  Systematically exploring repurposing effects of antihypertensives.

Authors:  Zach Shahn; Phoebe Spear; Helen Lu; Sharon Jiang; Suki Zhang; Neil Deshmukh; Shenbo Xu; Kenney Ng; Roy Welsch; Stan Finkelstein
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-06-21       Impact factor: 2.732

8.  Early ACEI/ARB use and in-hospital outcomes of acute myocardial infarction patients with systolic blood pressure <100 mmHg and undergoing percutaneous coronary intervention: Findings from the CCC-ACS project.

Authors:  Xuedong Zhao; Guanqi Zhao; Mengge Zhou; Ge Wang; Changsheng Ma; Sidney C Smith; Gregg C Fonarow; Louise Morgan; Bin Que; Hui Ai; Jing Liu; Dong Zhao; Shaoping Nie
Journal:  Front Cardiovasc Med       Date:  2022-09-29

9.  Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort.

Authors:  Yuan Lu; Mui Van Zandt; Yun Liu; Jing Li; Xialin Wang; Yong Chen; Zhengfeng Chen; Jaehyeong Cho; Sreemanee Raaj Dorajoo; Mengling Feng; Min-Huei Hsu; Jason C Hsu; Usman Iqbal; Jitendra Jonnagaddala; Yu-Chuan Li; Siaw-Teng Liaw; Hong-Seok Lim; Kee Yuan Ngiam; Phung-Anh Nguyen; Rae Woong Park; Nicole Pratt; Christian Reich; Sang Youl Rhee; Selva Muthu Kumaran Sathappan; Seo Jeong Shin; Hui Xing Tan; Seng Chan You; Xin Zhang; Harlan M Krumholz; Marc A Suchard; Hua Xu
Journal:  JAMA Netw Open       Date:  2022-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.